18 new oncology trials approved in Europe


Oncology Hero Oncology Hero

18 new oncology trials approved in Europe

Good morning, here is a concise selection of oncology and haematology trials and investigator opportunities in Europe.

AcTFirst: A phase III, open-label, multi-center, randomized study comparing AAA817+ARPI versus standard of care in adult participants with PSMA-positive metastatic castration-resistant prostate cancer

Sponsor: Novartis Pharma AG Phase: 3

Interested in offering this trial to suitable patients?

Register Investigator Interest

EURbG2: A European prospective study of unilateral retinoblastoma requiring enucleation, first-line or after neoadjuvant chemotherapy, with assessment of histological risk factors and biomarkers

Sponsor: Institut Curie Phase:

Interested in offering this trial to suitable patients?

Register Investigator Interest

ABCSG 64 / neoGRACE: Neoadjuvant Sacituzumab Govitecan versus Standard Chemotherapy in Endocrine-Nonresponsive ER+/HER2− Early Breast Cancer

Sponsor: Verein Zur Praevention Und Therapie Boesartiger Erkrankungen Austrian Breast And Colorectal Cancer Study Group Phase: 2

Interested in offering this trial to suitable patients?

Register Investigator Interest

THERANOVA (NMN-02/MEDOPP838): Adaptive Diagnostic and Therapeutic Radioligand Platform for Solid Tumors With Active Brain Metastases

Sponsor: Medica Scientia Innovation Research S.L. Phase:

Interested in offering this trial to suitable patients?

Register Investigator Interest

PATAGONIA: A Global, Multicentre, Phase II Platform Study of Datopotamab Deruxtecan-based Combinations in TROP2 NMR-positive Non-small Cell Lung Cancer

Sponsor: AstraZeneca AB Phase: 2

Interested in offering this trial to suitable patients?

Register Investigator Interest

Synergism of dendritic cell vaccination and anti-PD-L1 immune check-point blockade to sensitize recurrent glioblastoma to anti-tumoral immunity

Sponsor: Heinrich-Heine-Universitaet Duesseldorf Phase: 1

Interested in offering this trial to suitable patients?

Register Investigator Interest

M26-326: ABBV-253 in Adults With Advanced Solid Tumors

Sponsor: AbbVie Deutschland GmbH & Co. KG Phase:

Interested in offering this trial to suitable patients?

Register Investigator Interest

HARMONi-10: A phase 3 open-label study of ivonescimab versus durvalumab as consolidation therapy in unresectable stage III non-small cell lung cancer without progression after definitive platinum-based concurrent chemoradiotherapy

Sponsor: Summit Therapeutics Inc. Phase: 3

Interested in offering this trial to suitable patients?

Register Investigator Interest

METIMMOX-3: Biomarker-Selected Short-Course Oxaliplatin-Based Chemotherapy and Bevacizumab Alternating With Tislelizumab in Metastatic MSS/pMMR Colorectal Cancer

Sponsor: Akershus University Hospital Phase: 2

Interested in offering this trial to suitable patients?

Register Investigator Interest

DECEMBER: De-escalation of CDK4/6 inhibitors for ER-positive, HER2-negative metastatic breast cancer in complete response

Sponsor: Unicancer Phase: 3

Interested in offering this trial to suitable patients?

Register Investigator Interest

DREAMER: Intensified neoadjuvant-adjuvant management of resectable esophageal adenocarcinoma — multicentre, phase II, single-arm study

Sponsor: Centro Di Riferimento Oncologico Di Aviano Phase: 2

Interested in offering this trial to suitable patients?

Register Investigator Interest

A Phase III randomized open-label study of izalontamab brengitecan (BMS-986507) with osimertinib versus osimertinib alone or with platinum-based chemotherapy as first-line therapy in EGFR-mutant locally advanced or metastatic non-small cell lung cancer

Sponsor: Bristol-Myers Squibb Services Unlimited Company Phase: 3

Interested in offering this trial to suitable patients?

Register Investigator Interest

MESE: Phase II study of sertraline plus cisplatin or carboplatin and pemetrexed for unresectable epithelioid pleural mesothelioma

Sponsor: Centro Di Riferimento Oncologico Di Aviano Phase: 2

Interested in offering this trial to suitable patients?

Register Investigator Interest

FUTURE: Phase II prospective non-randomized diagnostic study of FAPI PET imaging and liquid biopsy in bladder cancer

Sponsor: Universita' Vita-salute S. Raffaele Phase: 2

Interested in offering this trial to suitable patients?

Register Investigator Interest

A Phase I/II, Multi-part, Open-label, Multicenter, First-in-human Trial to Evaluate Safety, Tolerability, Immunogenicity, and Signals of Efficacy of JJP-1008 as Monotherapy and in Combination in Participants with Advanced, Unresectable Skin Melanoma and Other Solid Tumors

Sponsor: JJP BIOLOGICS Sp. z o.o. Phase: 1, 2

Interested in offering this trial to suitable patients?

Register Investigator Interest

RUPISTAR: A Study in Patients With ESR1-Mutated ER-Positive, HER2-Negative Advanced Breast Cancer

Sponsor: Evexta Bio Phase: 3

Interested in offering this trial to suitable patients?

Register Investigator Interest

A Phase 3 Open-Label, Randomized Controlled Trial of T-bren (BL-M07D1) vs. Platinum-based Chemotherapy in Patients with HER2-expressing metastatic urothelial cancer with disease progression on or after anti-PD-(L)1-based therapy

Sponsor: Systimmune Inc. Phase: 3

Interested in offering this trial to suitable patients?

Register Investigator Interest

[89Zr]Zr-PSMA-N139 PET/CT Imaging in Primary and Recurrent Prostate Cancer

Sponsor: Radboud universitair medisch centrum Stichting Phase:

Not accepting new sites

Oncology Hero Trial Feed connects oncology professionals with relevant clinical trials.

For qualified healthcare and research professionals. Registration expresses investigator interest; it is not patient enrollment.

Oncology Hero

Sharing the latest updates in oncology

Read more from Oncology Hero

Oncology Hero 11 new oncology trials approved in Europe Good morning, here is a concise selection of oncology and haematology trials and investigator opportunities in Europe. A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1) Sponsor: Eli Lilly & Co. Phase: Interested in offering this trial to suitable patients? Register Investigator Interest A multicentre open-label phase I/Ib trial of melanoma-specific peptide vaccination (UniCanVax) combined...

Oncology Hero 9 new oncology trials approved in Europe Good morning, here is a concise selection of oncology and haematology trials and investigator opportunities in Europe. VIKTORIA-2: A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Gedatolisib with Endocrine Therapy and Palbociclib vs Endocrine Therapy and Ribociclib as First-Line Treatment in Patients With HR-Positive and HER2-Negative Advanced Breast Cancer Sponsor: Celcuity Inc. Phase: 3 Interested in offering...

Oncology Hero 12 new oncology trials approved in Europe Good morning, here is a concise selection of oncology and haematology trials and investigator opportunities in Europe. EORTC-2456-LCG-BTG: A randomized phase II study evaluating upfront SRT to all brain metastases followed by ivonescimab plus chemotherapy versus upfront ivonescimab plus chemotherapy in patients with asymptomatic active brain metastases from NSCLC. Sponsor: European Organisation For Research And Treatment Of Cancer Phase:...